ERCC5 and cancer: Zhao et al. [10] and He et al. [21], in their meta-analysis, attest that allele mutation of the XPG complementation group, rs17655 and Asp1104His, may increase the overall cancer risk but did not correlate these polymorphisms to a specific risk of cutaneous malignancies.